跳至主要内容
临床试验/ISRCTN81988253
ISRCTN81988253进行中(未招募)Unknown

Can vaccination against herpes zoster with Shingrix be associated with reduced risk for developing dementia?

GlaxoSmithKline (Sweden)0 个研究点目标入组 8,000 人开始时间: 2024年8月19日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
8,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • Patients that participated in the previous vaccination studies in Sweden will be included in this study. The date of inclusion will be when the first dose of either Shingrix or placebo was administered. Patients can be included at any point during the inclusion period and the associated prescreening and follow-up period will be associated with the inclusion date. Members of the synthetic control arm will have the same inclusion date as their associated patient from the vaccination study.

排除标准

  • Individuals without a Swedish personal identification number will be excluded. Individuals that have a confirmed dementia diagnosis in the pre-screening period will be excluded.

研究者

发起方
GlaxoSmithKline (Sweden)

相似试验